Clinical Trials Directory

Trials / Completed

CompletedNCT00006473

Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

A Phase II Study of Oxaliplatin in Relapsed and Refractory Non-Hodgkin's Lymphoma

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
72 (actual)
Sponsor
National Cancer Institute (NCI) · NIH
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Phase II trial to study the effectiveness of oxaliplatin in treating patients who have relapsed or refractory non-Hodgkin's lymphoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

Detailed description

OBJECTIVES: I. Determine the response rate to oxaliplatin in patients with relapsed or refractory non-Hodgkin's lymphoma. II. Determine the treatment-related toxicity of this drug in these patients. OUTLINE: This is a multicenter study. Patients are stratified according to histologic subtype (indolent vs aggressive). Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 21 days for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A maximum of 72 patients will be accrued for this study within 2-3 years.

Conditions

Interventions

TypeNameDescription
DRUGoxaliplatinGiven IV

Timeline

Start date
2000-09-01
Primary completion
2006-02-01
First posted
2003-01-27
Last updated
2013-01-23

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00006473. Inclusion in this directory is not an endorsement.